Skip to main content
Category

Treatments

OncLive
ResearchTreatments

Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results

*November 2023* Although biomarker testing is crucial for determining optimal targeted therapies for patients with advanced non–small cell lung cancer (NSCLC), the time between conducting these tests and receiving results poses challenges for both oncologists and patients, according to Stephen V. Liu, MD. “There are cases where we need to…
laurabbook@gmail.com
December 27, 2023
OncLive
ResearchTreatments

Discussing Biomarkers and Best Options in NSCLC

*November 2023* In this video, Hossein Borghaei, MS, DO, chief of Thoracic Medical Oncology, professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic malignancies, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium®.…
laurabbook@gmail.com
December 27, 2023
Targeted Oncology
ResearchTreatments

Frontline Combinations Better Survival Rates in EGFRm Lung Cancer

*November 2023* First-line combination treatment regimens are improving progression-free survival (PFS) rates in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to Julia Rotow, MD.1 Prior to November 2023, the main first-line therapy utilized for the treatment of patients with EGFR-mutated lung cancer was osimertinib (Tagrisso) monotherapy, based on the phase…
laurabbook@gmail.com
December 27, 2023
OncLive
ResearchTreatments

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

*October 2023* Take home message: Comparison Dato-DXd, a novel TROP2-directed antibody-drug conjugate, to docetaxel in pretreated advanced/metastatic non-small cell lung cancer (NSCLC) patients, revealing significantly improved progression-free survival with Dato-DXd, especially in non-squamous histology patients, while demonstrating a manageable safety profile and ongoing evaluation of overall survival. (From OncoAlert) The Trop-2…
laurabbook@gmail.com
December 27, 2023